Overview

• Life sciences solutions provider's fiscal Q1 revenue rose 1%, beating analyst expectations

• Adjusted EPS for fiscal Q1 missed analyst expectations

• Company authorized $250 mln share repurchase program through 2028

Outlook

• Azenta expects full-year 2026 organic revenue growth of 3% to 5%

• Company anticipates 300 basis points expansion in adjusted EBITDA margin for 2026

• Azenta expects stronger second half of 2026 supported by execution initiatives

Result Drivers

• GROSS MARGIN CHALLENGES - Gross margin decreased due to lost cost leverage from lower sales volumes and rework costs on Automated Stores projects

• FREE CASH FLOW - Strong free cash flow was generated, reflecting focus on operational discipline and working capital management, per CEO John Marotta

• MULTIOMICS GROWTH - Multiomics revenue increased 1% year over year, driven by growth in Next Generation Sequencing and Gene Synthesis

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Azenta Inc is $41.00, about 11.1% above its February 3 closing price of $36.91

• The stock recently traded at 44 times the next 12-month earnings vs. a P/E of 39 three months ago

Press Release: ID:nPn1gswPa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)